Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Gusperimus

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Gusperimus?

Gusperimus is an investigational drug.

There have been 4 clinical trials for Gusperimus. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2011.

The most common disease conditions in clinical trials are Granulomatosis with Polyangiitis, Nephritis, and Lupus Nephritis. The leading clinical trial sponsors are Nippon Kayaku Co.,Ltd., Nordic Pharma SAS, and [disabled in preview].

There is one US patent protecting this investigational drug and thirteen international patents.

Recent Clinical Trials for Gusperimus
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's GranulomatosisNordic Pharma SASPhase 3
Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic RejectionNippon Kayaku Co.,Ltd.N/A
Phase II Study on Gusperimus in Patients With Refractory Wegener's GranulomatosisNippon Kayaku Co.,Ltd.Phase 2

See all Gusperimus clinical trials

Clinical Trial Summary for Gusperimus

Top disease conditions for Gusperimus
Top clinical trial sponsors for Gusperimus

See all Gusperimus clinical trials

US Patents for Gusperimus

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gusperimus   Start Trial Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
Gusperimus   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Gusperimus   Start Trial Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.